TEAM

“First-rate team with experience in drug development which will ensure efficient management”

MANAGEMENT TEAM

The company is headed by a first-rate team with experience in drug development, regulatory, neuronal diseases, venture capital and licensing.

Pablo Ferrón

Chief Executive Officer

+ - Read More

+ - Biography

Master’s degree in Synthetic and Industrial Chemistry. He participated in the design and synthesis of the first MP compound. He has previous entrepreneur experience (in 2010, founded an industrial start-up: Gomavial Solutions). He is now leader of Miramoon Pharma.

Prof. Dr. Jesús María Aizpurua

Chief Scientific Officer

+ - Read More

+ - Biography

Expert in drug synthesis and click chemistry. He leads the research group Sustainable Catalysis: Methods and Computation in San Sebastián. He is the author of 120 scientific publications (H = 32), 5 patents and supervised 20 doctoral theses, and directed 19 research projects. He ensures the rapid synthesis of MPs compounds libraries when required.

Dr. MD Adolfo López de Munain

Chief Medical Officer

+ - Read More

+ - Biography

Expert in neurodegenerative diseases and has permanent contact with patients affected by such conditions.

He is author or co-author of 225 reviewed articles, and 26 book chapters. He provides medical and clinical expertise and, as a national authority in the area of neuroscience, facilitates access to national pharmaceutical companies and institutions.

Naiara Pineda

Chief Financial Officer

+ - Read More

+ - Biography

Degree in Business Administration. Postgraduate in Financial Management from the University of Deusto. Expert in Accounting and Auditing, in Innovation and Management, and in Marketing Management and International Relations. Expert in LCC (Life Cycle Costing H2020) cost analysis.

Founder of FinBox, leading the economic-financial consulting area. I have developed and participated in the strategies and policies according to our clients and brand services: Costing, Pricing, Cash and Investment Analysis with financing solutions, investment funds, grants and banking products.

Glória Martín

Regulatory Affairs Manager

+ - Read More

+ - Biography

Regulatory Affairs with +25 years of experience in the pharmaceutical industry R&D and +5 as a Regulatory Affairs consultant to start-up and biotech companies.

Expertise encompasses EU and US regulations and procedures in different therapeutic areas and including small molecules, biologic and advanced therapies products.

Inveniam Group

Business Development Manager

+ - Read More

+ - Biography

An expert team of consultants from the Inveniam Group will take care of all the activities related to market access, such as health economics analysis and market research. Inveniam will also provide support on public and private funding strategy and execution.

R&D TEAM

We are a multidisciplinary and experienced team made up of biologists, chemists and clinicians, amongst others, who work tirelessly to make our goals a reality.

Dr. Javier Ruiz

Biology Director

+ - Read More

+ - Biography

PhD in Biological Sciences with 5 years of Postdoctoral experience at the University of California, San Francisco and >20 years of experience in ocular diseases. He led the sensory neurodegeneration group at Biodonostia Health Research Institute (2010-2020); 14 research projects; 25 publications in indexed journals and 4 doctoral theses. Accredited with Excellence in Research (I3 Program, I3/2019/384) and in Human Genetics (AEGH).

In 2021 he was hired by Miramoon Pharma through a Torres Quevedo contract (PTQ2019-010412) to lead the biology area of the company.

Dr. Ainara Vallejo

Pharmacology Director

+ - Read More

+ - Biography

PhD in Neurosciences, expert in bioactivity evaluation. Demonstrated experience in the biomedical area with 26 scientific publications, 3 international patents and has supervised 4 doctoral theses.

She has directed several national and international competitive research projects, many of them in muscular dystrophies. She provides the project with access to test laboratories with biological materials, cell and animal models, and various mass testing methods for the selection of “Hit” and “Lead” molecules, etc.

Dr. J. Ignacio Miranda

Medicinal Chemistry Director

+ - Read More

+ - Biography

Expert in the design of “In silico” molecules against biological targets. The different cooperation activity with many groups with the result of 45 publications (H = 15).

He has co-supervised 1 doctoral thesis. Provides the project with technical knowledge of structural and bioinformatic analysis of molecules and targets.

Prof. Dr. Jesús María Aizpurua

Chief Scientific Officer

+ - Read More

+ - Biography

Expert in drug synthesis and click chemistry. He leads the research group Sustainable Catalysis: Methods and Computation in San Sebastián. He is the author of 120 scientific publications (H = 32), 5 patents and supervised 20 doctoral theses, and directed 19 research projects. He ensures the rapid synthesis of MPs compounds libraries when required.

ADVISORY BOARD

Combined expertise in basic research and clinical practice.

Advisory Board composed of internationally renowned experts in Medicinal Chemistry, Clinical Area, Regulatory, Pharmaceutical Technology and Pharmacology of Neurodegenerative, Rare Diseases and Retinal disorders.

Dr. MD. Cristina Irigoyen

Retinal Disorders-Clinician

+ - Read More

+ - Biography

Medicine and Surgery, specialized in Ophthalmology and retina (Hospital Universitario Donostia).

Published 22 articles and participated in 10 clinical trials and obtained several grants for clinical studies in Retinitis Pigmentosa.

Dr. Francisco J. Gil-Bea

Rare Diseases

+ - Read More

+ - Biography

Principal Investigator from 2010 to 2014 at CIMA of the University of Navarra, with funding from the Alzheimer’s Association of the USA.

Since 2015 principal investigator at the Biodonostia Institute.+15 years of experience in the study of neurodegeneration, published more than 40 publications (H=23), and supervised 2 PhDs and several master students.

Dr. Helmut Buschmann

MedChemi

+ - Read More

+ - Biography

Chemist with + 20 years’ experience in drug discovery and development, guided 15 novel drug classes into clinical phases and was appointed as inventor in over 200 patents.

Prof. Virginia Arechavala – Gomeza

Orphan Drugs

+ - Read More

+ - Biography

Pharmacist (University of the Basque Country, Spain), MSc in Immunopharmacology (University of Strathclyde) and PhD in Neurology (King’s College London). She leads the Neuromuscular Research group at Biobizkaia Health Research Institute as an Ikerbasque Research Professor.

She has over 20 years’ experience in research in neuromuscular disorders, has participated in the development of several orphan drugs and chairs an international network of researchers in the field of nucleic acid therapeutics. She has authored many highly-cited scientific publications, serves in several Spanish and International grant review panels and has collaborated as an expert with the European Medicines Agency.

Dr. MD. Pedro de la Villa

Retinal Disorders-R&D

+ - Read More

+ - Biography

Author of +75 papers, Director of 15 PhD theses and Principal Investigator of 15 national and international research projects.

Research in neurophysiology of the visual system, retinal physiology, and neuromuscular physiology.

This website uses cookies to remember users and understand ways to enhance their experience.    More info
Privacidad